JP2013536168A5 - - Google Patents

Download PDF

Info

Publication number
JP2013536168A5
JP2013536168A5 JP2013519858A JP2013519858A JP2013536168A5 JP 2013536168 A5 JP2013536168 A5 JP 2013536168A5 JP 2013519858 A JP2013519858 A JP 2013519858A JP 2013519858 A JP2013519858 A JP 2013519858A JP 2013536168 A5 JP2013536168 A5 JP 2013536168A5
Authority
JP
Japan
Prior art keywords
ylmethyl
alkylene
alkyl
heterocyclyl
heteroaryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013519858A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013536168A (ja
JP6081354B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2011/044254 external-priority patent/WO2012009678A1/en
Publication of JP2013536168A publication Critical patent/JP2013536168A/ja
Publication of JP2013536168A5 publication Critical patent/JP2013536168A5/ja
Application granted granted Critical
Publication of JP6081354B2 publication Critical patent/JP6081354B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013519858A 2010-07-16 2011-07-15 治療活性組成物およびそれらの使用方法 Active JP6081354B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US36507210P 2010-07-16 2010-07-16
US61/365,072 2010-07-16
PCT/US2011/044254 WO2012009678A1 (en) 2010-07-16 2011-07-15 Therapeutically active compositions and their method of use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016166461A Division JP2017039725A (ja) 2010-07-16 2016-08-29 治療活性組成物およびそれらの使用方法

Publications (3)

Publication Number Publication Date
JP2013536168A JP2013536168A (ja) 2013-09-19
JP2013536168A5 true JP2013536168A5 (cg-RX-API-DMAC10.html) 2014-08-21
JP6081354B2 JP6081354B2 (ja) 2017-02-15

Family

ID=44629416

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2013519858A Active JP6081354B2 (ja) 2010-07-16 2011-07-15 治療活性組成物およびそれらの使用方法
JP2016166461A Withdrawn JP2017039725A (ja) 2010-07-16 2016-08-29 治療活性組成物およびそれらの使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2016166461A Withdrawn JP2017039725A (ja) 2010-07-16 2016-08-29 治療活性組成物およびそれらの使用方法

Country Status (10)

Country Link
US (2) US20130184222A1 (cg-RX-API-DMAC10.html)
EP (1) EP2593425B1 (cg-RX-API-DMAC10.html)
JP (2) JP6081354B2 (cg-RX-API-DMAC10.html)
CN (1) CN103097340B (cg-RX-API-DMAC10.html)
AU (1) AU2011278998B2 (cg-RX-API-DMAC10.html)
BR (1) BR112013001122B1 (cg-RX-API-DMAC10.html)
CA (1) CA2805669C (cg-RX-API-DMAC10.html)
ES (1) ES2704862T3 (cg-RX-API-DMAC10.html)
MX (1) MX342951B (cg-RX-API-DMAC10.html)
WO (1) WO2012009678A1 (cg-RX-API-DMAC10.html)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102985557B (zh) 2009-03-13 2018-06-15 安吉奥斯医药品有限公司 用于细胞增殖相关病症的方法和组合物
PE20120693A1 (es) 2009-06-29 2012-07-04 Agios Pharmaceuticals Inc Compuestos heterociclos como moduladores de la piruvato cinasa m2 (pkm2)
EP2525790B1 (en) 2009-10-21 2020-05-27 Agios Pharmaceuticals, Inc. Methods and compositions for cell-proliferation-related disorders
WO2011050210A1 (en) 2009-10-21 2011-04-28 Agios Pharmaceuticals, Inc. Methods and compositions for cell-proliferation-related disorders
PT3406251T (pt) 2011-05-03 2024-01-24 Agios Pharmaceuticals Inc Ativadores da piruvato-cinase para utilização em terapia
CN102827073A (zh) 2011-06-17 2012-12-19 安吉奥斯医药品有限公司 治疗活性组合物和它们的使用方法
CN102827170A (zh) 2011-06-17 2012-12-19 安吉奥斯医药品有限公司 治疗活性组合物和它们的使用方法
MX342326B (es) 2011-09-27 2016-09-26 Novartis Ag 3-pirimidin-4-il-oxazolidin-2-onas como inhibidoras de idh mutante.
CA2856591A1 (en) * 2011-11-25 2013-05-30 Hendrik Helmke 2-iodoimidazole derivatives
US9877962B2 (en) 2011-12-30 2018-01-30 Marc Henry Pitty Piperazinyl derivatives for the treatment of cancer
FR2985256B1 (fr) * 2011-12-30 2016-03-04 Pitty Marc Henry Derives piperazinyles pour le traitement de cancers
SMT201800334T1 (it) 2012-01-06 2018-09-13 Agios Pharmaceuticals Inc Composti terapeuticamente attivi e loro metodi di utilizzo
ES2698625T3 (es) * 2012-01-19 2019-02-05 Agios Pharmaceuticals Inc Compuestos terapéuticamente activos y sus métodos de uso
US9474779B2 (en) 2012-01-19 2016-10-25 Agios Pharmaceuticals, Inc. Therapeutically active compositions and their methods of use
UY34632A (es) 2012-02-24 2013-05-31 Novartis Ag Compuestos de oxazolidin- 2- ona y usos de los mismos
EP2827861A4 (en) * 2012-03-19 2016-03-16 Aposignal Bioscience Llc COMPOSITION AND METHODS FOR CELLULAR MODULATION
WO2014062511A1 (en) * 2012-10-15 2014-04-24 Agios Pharmaceuticals, Inc. Therapeutic compounds and compositions
US9296733B2 (en) 2012-11-12 2016-03-29 Novartis Ag Oxazolidin-2-one-pyrimidine derivative and use thereof for the treatment of conditions, diseases and disorders dependent upon PI3 kinases
TWI648274B (zh) 2013-02-15 2019-01-21 英商葛蘭素史克智慧財產發展有限公司 作為激酶抑制劑之雜環醯胺類 （二）
EA027879B1 (ru) 2013-02-22 2017-09-29 Пфайзер Инк. ПРОИЗВОДНЫЕ ПИРРОЛО[2,3-d]ПИРИМИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ ЯНУС-РОДСТВЕННЫХ КИНАЗ (JAK)
CA2903979A1 (en) * 2013-03-14 2014-09-18 Novartis Ag 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh
WO2014184272A2 (en) * 2013-05-14 2014-11-20 Medizinische Hochschule Hannover Means and methods for treating cancer
WO2015003355A2 (en) 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
MX375030B (es) 2013-07-11 2025-03-06 Agios Pharmaceuticals Inc Compuestos de n,6-bis(aril o heteroaril)-1,3,5-triazin-2,4-diamina como inhibidores de idh2 mutantes para el tratamiento de cancer.
CN105593215B (zh) 2013-07-11 2019-01-15 安吉奥斯医药品有限公司 用于治疗癌症的作为idh2突变体抑制剂的2,4-或4,6-二氨基嘧啶化合物
WO2015003360A2 (en) 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
WO2015010297A1 (en) * 2013-07-25 2015-01-29 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
KR101861869B1 (ko) * 2013-09-10 2018-05-28 경희대학교 산학협력단 신규한 비스-아미드 유도체 및 이의 용도
PH12021551647A1 (en) 2014-03-14 2022-06-06 Agios Pharmaceuticals Inc Pharmaceutical compositions of therapeutically active compounds
WO2016024185A1 (en) 2014-08-12 2016-02-18 Pfizer Inc. Pyrrolo[2,3-d]pyrimidine derivatives useful for inhibiting janus kinase
LT3202766T (lt) 2014-10-01 2020-05-11 Daiichi Sankyo Company, Limited Izoksazolo darinys, kaip mutuotos izocitrato dehidrogenazės 1 inhibitorius
JP6672288B2 (ja) 2014-10-23 2020-03-25 バイエル・ファルマ・アクティエンゲゼルシャフト 腫瘍の治療のためのｍｉｄｈ１阻害剤としての１−シクロヘキシル−２−フェニルアミノベンゾイミダゾール
ES2905564T3 (es) 2014-12-22 2022-04-11 Us Health Inhibidores mutantes de IDH1 útiles para tratar el cáncer
MX384883B (es) 2015-06-11 2025-03-14 Agios Pharmaceuticals Inc Métodos para usar activadores de piruvato cinasa.
CN108026052B (zh) * 2015-07-16 2021-10-08 德国癌症研究公共权益基金会 作为mIDH1抑制剂的5-羟烷基苯并咪唑类
MD3362066T2 (ro) 2015-10-15 2022-08-31 Les Laboratoires Servier Sas Terapie combinată pentru tratamentul tumorilor maligne
HUE067449T2 (hu) 2015-10-15 2024-10-28 Servier Lab Ivozidenib, citarabin és daunorubicin vagy idarubicin kombinációs terápa akut mielogén leukémia kezelésére
TWI729094B (zh) * 2016-03-22 2021-06-01 大陸商正大天晴藥業集團股份有限公司 內磺醯胺化合物及其使用方法
EP3444237B1 (en) 2016-03-22 2020-10-28 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Iridinesulfonamide compound and use method thereof
US9975885B2 (en) * 2016-04-28 2018-05-22 Purdue Research Foundation Broad-spectrum non-covalent coronavirus protease inhibitors
EP3686191B1 (en) * 2017-09-22 2022-12-14 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Crystalline sulfamide compound
GB201721957D0 (en) * 2017-12-27 2018-02-07 Bp Oil Int Methods for preparing fuel additives
GB201721961D0 (en) 2017-12-27 2018-02-07 Bp Oil Int Methods for preparing fuel additives
GB201721964D0 (en) 2017-12-27 2018-02-07 Bp Oil Int Methods for preparing fuel additives
GB201721960D0 (en) 2017-12-27 2018-02-07 Bp Oil Int Methods for preparing fuel additives
GB201721967D0 (en) 2017-12-27 2018-02-07 Bp Oil Int Methods for preparing fuel additives
US11799898B2 (en) * 2018-02-20 2023-10-24 Darktrace Holdings Limited Method for sharing cybersecurity threat analysis and defensive measures amongst a community
CN108484522A (zh) * 2018-04-25 2018-09-04 山东百诺医药股份有限公司 4-(1,2,4-噁二唑-3-基)苯胺的制备方法
US10980788B2 (en) 2018-06-08 2021-04-20 Agios Pharmaceuticals, Inc. Therapy for treating malignancies
CN109535025B (zh) * 2018-12-18 2022-09-09 尚科生物医药（上海）有限公司 一种艾伏尼布中间体3,3-二氟环丁胺盐酸盐的制备方法
CN110283096A (zh) * 2019-07-03 2019-09-27 三峡大学 一种Cu-MOF催化的ɑ-胺基酰胺类化合物及其制备方法
US20230192671A1 (en) * 2020-05-15 2023-06-22 Purdue Research Foundation Compounds for the treatment of sars
WO2022221686A1 (en) * 2021-04-15 2022-10-20 Pardes Biosciences, Inc. Inhibitors of cysteine proteases and methods of use thereof
JP2024542969A (ja) 2021-11-02 2024-11-19 インシリコ メディシン アイピー リミテッド コロナウイルス感染を処置するためのｓａｒｓ－ｃｏｖ－２阻害剤
CN113845440A (zh) * 2021-11-04 2021-12-28 沈阳药科大学 基于ugi反应合成的非天然肽类idh1抑制剂及其制法和应用
CN118184599A (zh) * 2024-02-29 2024-06-14 重庆药友制药有限责任公司 一种阿莫奈韦中间体的制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60023920T2 (de) * 1999-08-27 2006-07-20 Sugen, Inc., South San Francisco Phosphatmimetika und Verfahren zur Behandlung mit Phosphataseinhibitoren HIBITOREN
US20040067234A1 (en) * 2002-07-11 2004-04-08 Paz Einat Isocitrate dehydrogenase and uses thereof
CN101137414A (zh) * 2004-12-31 2008-03-05 欧兰拓制药股份有限公司 多环双酰胺mmp抑制剂
AU2008345225A1 (en) * 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
FR2932483A1 (fr) * 2008-06-13 2009-12-18 Cytomics Systems Composes utiles pour le traitement des cancers.
US8685660B2 (en) * 2008-09-03 2014-04-01 The Johns Hopkins University Genetic alterations in isocitrate dehydrogenase and other genes in malignant glioma

Similar Documents

Publication Publication Date Title
EP2968287B1 (en) N-acyl-n'-(pyridin-2-yl) ureas and analogs exhibiting anti-cancer and anti-proliferative activities
JP6309519B2 (ja) Ｎ置換ベンズアミド及びその使用方法
JP2015506985A5 (cg-RX-API-DMAC10.html)
JP2010532386A5 (cg-RX-API-DMAC10.html)
JP2019156852A (ja) Ａｓｋ１阻害剤の固体形態
JP2008535871A5 (cg-RX-API-DMAC10.html)
JP2019513714A (ja) 置換ベンズアミド及びその使用方法
JP6081354B2 (ja) 治療活性組成物およびそれらの使用方法
TW200817350A (en) Biaryloxymethylarenecarboxylic acids
RU2018136888A (ru) Нафтиридины в качестве антагонистов интегрина
JP2018519323A5 (cg-RX-API-DMAC10.html)
RU2007141892A (ru) 5-метил-1-(замещенный фенил)-2-(1н)-пиридон для производства медикаментов для лечения фиброза в органах и тканях
JP2010533715A5 (cg-RX-API-DMAC10.html)
US7053094B2 (en) Compositions and methods for treating heart failure
JP2010532387A5 (cg-RX-API-DMAC10.html)
RU2015144385A (ru) Ациклические цианоэтилпиразолопиридоны в качестве ингибиторов янус-киназы
JP2004307440A (ja) ２−アミノ‐１，３‐プロパンジオール誘導体とその付加塩
SK2962002A3 (en) Carboxylic acid amides, medicaments containing these compounds and the use and production thereof
JP2019206529A (ja) 新規抗癌剤
JP2011506501A5 (cg-RX-API-DMAC10.html)
KR20120092655A (ko) Ｃｎｓ 장애 치료용 옥사졸린 유도체
RU2005119644A (ru) 4-оксо-1-(3-замещенный фенил-1,4-дигидро-1,8-нафтиридин -3-карбоксамиды в качестве ингибиторов фосфодиэстеразы-4
RU2010132911A (ru) Гидроксилированные пиримидилциклопентаны в качестве ингибиторов протеинкиназы (акт)
WO2001070723A1 (en) Benzothiophene derivatives and medicinal use thereof
JP2008533063A5 (cg-RX-API-DMAC10.html)